Showing results (121-130 of 357) with videos related to
Sort By:
Pageof 36
Oncotargets and Therapy|December 4, 2010
The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancerThomas Powles, Siobhan McFaul, Justin Stebbing, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2008
The risks and incidence of K65R and L74V mutations and subsequent virologic responsesLaura Waters, Mark Nelson, Sundhiya Mandalia, et al.Molecular Biotechnology|May 8, 2023
Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung AdenocarcinomaPeng Wang, Zhiqiang Wang, Yanke Lin, et al.Molecular & Cellular Proteomics : MCP|June 20, 2015
Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative ProteomicsJustin Stebbing, Hua Zhang, Yichen Xu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcomaJustin Stebbing, Adam Sanitt, Alastair Teague, et al.Frontiers in Oncology|January 10, 2022
A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung AdenocarcinomaLiping Zhu, Zhiqiang Wang, Yilan Sun, et al.Biomarkers in Medicine|March 28, 2012
Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3´-deoxy-3´-fluorothymidine PET: a pilot studyKaiyumars Contractor, Eric O Aboagye, Jimmy Jacob, et al.Expert Review of Anticancer Therapy|September 21, 2011
Determination of cut-offs for circulating tumor cell measurement in metastatic cancerJimmy Jacob, Jonathan Krell, Leandro Castellano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 studyJonathan Shamash, Jimmy Jacob, Samir Agrawal, et al.Frontiers in Oncology|April 25, 2022
Targeting ALK Rearrangements in NSCLC: Current State of the ArtLing Peng, Liping Zhu, Yilan Sun, et al.Pageof 36